Citius Pharmaceuticals (NASDAQ:CTXR) & Relmada Therapeutics (NASDAQ:RLMD) Head to Head Contrast

Relmada Therapeutics (NASDAQ:RLMD) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Relmada Therapeutics and Citius Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$79.98 million	($1.80)	-2.73
Citius Pharmaceuticals	N/A	N/A	-$37.43 million	($3.37)	-0.23

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Relmada Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Profitability

This table compares Relmada Therapeutics and Citius Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-269.49%	-205.22%
Citius Pharmaceuticals	N/A	-55.93%	-31.00%

Analyst Recommendations

This is a summary of recent ratings and price targets for Relmada Therapeutics and Citius Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	0	2	0	2.33
Citius Pharmaceuticals	1	2	1	0	2.00

Relmada Therapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 93.13%. Citius Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 681.25%. Given Citius Pharmaceuticals’ higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than Relmada Therapeutics.

Insider & Institutional Ownership

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats Relmada Therapeutics on 6 of the 11 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.